In the BioHarmony Drug Report Database

"Preview" Icon

Regadenoson

Lexiscan, Rapiscan (regadenoson) is a small molecule pharmaceutical. Regadenoson was first approved as Lexiscan on 2008-04-10. It has been approved in Europe to treat myocardial perfusion imaging. The pharmaceutical is active against adenosine receptor A2a. In addition, it is known to target adenosine receptor A1, adenosine receptor A2b, and adenosine receptor A3. Lexiscan’s patents are valid until 2027-02-02 (FDA).

 

Trade Name

 

Rapiscan
 

Common Name

 

regadenoson
 

ChEMBL ID

 

CHEMBL3989695
 

Indication

 

myocardial perfusion imaging
 

Drug Class

 

Adenosine A receptor agonists

Image (chem structure or protein)

Regadenoson structure rendering